drugset
Drugs / TAR-210
last change Mar 2026 re-read 3 minutes ago

TAR-210

Developed for
urinary bladder neoplasm
Investigated by
Janssen Research & Development, LLC

Trials 1

today NCT06919965 · Ph 3
202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT06919965 Sep 2025 → Apr 2028 expected urinary bladder neoplasm Janssen Research & Development, LLC Recruiting No outcome recorded

Press releases naming this drug 6 releases

DateIssuerRelease
2026-03-13 Janssen Research & Development, LLC Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate‑risk non–muscle-invasive bladder cancer jnj.com ↗
2026-03-13 Janssen Research & Development, LLC Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancer jnj.com ↗
2024-05-06 Janssen Research & Development, LLC TAR-210 results show 90% recurrence-free survival and 90% complete response in patients with high-risk and intermediate-risk non–muscle-invasive bladder cancer, respectively jnj.com ↗
2024-05-05 Janssen Research & Development, LLC TAR-210 results show 90% recurrence-free survival and 90% complete response in patients with high-risk and intermediate-risk non–muscle-invasive bladder cancer, respectively jnj.com ↗
2023-10-22 Janssen Research & Development, LLC First Results with Erdafitinib-Releasing Intravesical Delivery System (TAR-210) Show Early Evidence of Positive Clinical Activity in Patients with Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor Receptor Alterations jnj.com ↗
2023-10-22 Janssen Research & Development, LLC First Results with Erdafitinib-Releasing Intravesical Delivery System (TAR-210) Show Early Evidence of Positive Clinical Activity in Patients with Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor Receptor Alterations jnj.com ↗

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as TAR-210 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06919965 ↗